CLINICAL TRIAL: COMBINED TREATMENT WITH BORTEZOMIB & DACARBAZINE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 研究中心，而研究中心不一定是研究者所在的机构。 假设硼替佐米和达卡巴嗪联合治疗将增强黑色素瘤和软组织肉瘤的疗效。 具体目标是：（1）确定达卡巴嗪和硼替佐米每周联合给药的推荐剂量;（2）确定最大耐受剂量组合;（3）观察反应率、反应持续时间、进展时间和治疗时间（抗肿瘤活性和治疗耐受性的衡量指标）方面的抗肿瘤活性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The hypotheses is that combined treatment with bortezomib and dacarbazine will result in enhanced therapeutic efficacy in melanoma and soft tissue sarcoma. The specific Aims are to : (1) Determine the recommended doses for the combination dacarbazine and bortezomib administered weekly; (2) Determine the maximum tolerated dose combination; and (3) Observe anti-tumor activity in terms of response rate(s), duration of response, time to progression, and time on treatment (a measure of both antitumor activity and treatment tolerance).